{
    "clinical_study": {
        "@rank": "45242", 
        "acronym": "AH104", 
        "arm_group": [
            {
                "arm_group_label": "ETI-204", 
                "arm_group_type": "Experimental", 
                "description": "Intravenously (IV), single dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenously (IV), single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerability and pharmacokinetics (PK) of a single intravenous\n      (IV) dose of ETI-204 in adult volunteers."
        }, 
        "brief_title": "A Study to Assess the Safety, Tolerability and PK of a Single IV Dose of ETI-204 in Adult Volunteers", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Inhalational Anthrax", 
        "condition_browse": {
            "mesh_term": "Anthrax"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Females or males \u2265 18 years of age\n\n          2. All females, regardless of childbearing potential, must have a negative serum beta\n             human chorionic gonadotropin (\u03b2-hCG)  pregnancy test at Screening and Day -1\n\n          3. Females of childbearing potential (i.e., not postmenopausal or surgically sterile)\n             must agree to practice abstinence or to use a medically accepted method of\n             contraception from the time of Screening through 30 days after final study visit.\n             Acceptable methods of contraception include diaphragm with spermicide; sponge with\n             spermicide; condom with spermicide; or intrauterine device with condom or spermicide.\n             The following contraceptive methods are acceptable only when used with a condom and\n             spermicide: birth control pills, birth control patches, vaginal ring, hormone under\n             the skin, or hormone injections\n\n          4. Postmenopausal females, defined as females who have had amenorrhea for at least 12\n             months either naturally or following cessation of all exogenous hormonal treatments\n             and have a follicle stimulating hormone (FSH) level of > 40 mIU/mL at Screening\n\n          5. Females who have undergone surgical sterilization, including hysterectomy, bilateral\n             oophorectomy, bilateral salpingectomy, tubal ligation, or tubal essure\n\n          6. Males must agree to practice abstinence or use a condom with spermicide and refrain\n             from sperm donation during the study and for 30 days after the final study visit\n\n          7. Provide written informed consent\n\n          8. Willing to comply with study restrictions\n\n        Exclusion Criteria:\n\n          1. Pregnant or lactating woman\n\n          2. Clinically significant comorbidity that would interfere with completion of the study\n             procedures or objectives, or compromise the subject's safety\n\n          3. Seated systolic blood pressure (BP) \u2265 150 mmHg or \u2264 90 mmHg or diastolic BP  \u2265 95\n             mmHg\n\n          4. Use of H1 receptor antagonists (i.e. antihistamines) within 5 days prior to Day 1\n\n          5. Evidence of drug or alcohol abuse as determined by the Investigator within 6 months\n             of Day 1\n\n          6. Positive test result for drugs of abuse (with the exception of medically prescribed\n             drugs) at Screening or on Day -1\n\n          7. Positive test for alcohol at Screening; exclusion is subject to the Investigator's\n             discretion; subjects who test positive for alcohol at Day -1 are excluded from the\n             study\n\n          8. Treatment with an investigational agent within 30 days of Day 1 or within five\n             half-lives of the investigational agent at Day 1 (whichever is longer)\n\n          9. Congenital or acquired immunodeficiency syndrome\n\n         10. Prior solid organ or bone marrow transplant\n\n         11. Positive test for Hepatitis B (surface antigen), Hepatitis C, or human\n             immunodeficiency virus (HIV) at Screening\n\n         12. History of prior treatment for anthrax exposure or prior anthrax infection\n\n         13. Prior immunization with any approved or investigational anthrax vaccine or prior\n             treatment with an investigational anthrax treatment (i.e., ETI-204, raxibacumab, or\n             anthrax immune globulin)\n\n         14. Military personnel deployed in 1990 or after, unless the subject can provide\n             documentation demonstrating they have not previously received any approved or\n             investigational anthrax vaccine\n\n         15. Use of systemic steroids, immunosuppressive agents, anticoagulants, or\n             anti-arrhythmics within 1 year prior to Day 1.  A single short course (i.e., less\n             than 14 days) of systemic steroid therapy is allowed provided it concluded more than\n             6 months prior to Day 1\n\n         16. Donation or loss of > 500 mL of blood within 30 days or plasma within 7 days of Day 1\n\n         17. Prior stroke, epilepsy, relapsing or degenerative central nervous system disease, or\n             relapsing or degenerative ocular disease\n\n         18. Myocardial infarction or acute coronary syndrome in the past 5 years, active angina\n             pectoris, or heart failure (New York Heart Association scale > 1)\n\n         19. History of chronic liver disease\n\n         20. Calculated creatinine clearance (CrCl) of < 30 mL/min using the Cockcroft-Gault\n             equation\n\n         21. Any clinically significant abnormality, in the Investigator's opinion, on\n             electrocardiogram (ECG) or clinical laboratory tests (hematology, clinical chemistry,\n             or urinalysis) at Screening; Out of range results may be repeated to confirm.\n\n         22. History of allergic or hypersensitivity reactions to other therapeutic antibodies or\n             immunoglobulins\n\n         23. History of any malignant neoplasm within the last 5 years, with the exception of\n             adequately treated localized or in situ non-melanoma carcinoma of the skin (i.e.,\n             basal cell carcinoma) or the cervix\n\n         24. Subjects who, in the opinion of the Investigator, are not suitable candidates for\n             enrollment or who may not comply with the requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "280", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929226", 
            "org_study_id": "AH104"
        }, 
        "intervention": [
            {
                "arm_group_label": "ETI-204", 
                "description": "Monoclonal Antibody", 
                "intervention_name": "ETI-204", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo comparator", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological", 
                "other_name": "Placebo comparator"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "Covance Clinical Research Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers", 
        "overall_official": [
            {
                "affiliation": "Covance Clinical Research Unit Inc.", 
                "last_name": "Alex King, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Covance Clinical Research - Evansville, IN", 
                "last_name": "Lori Sieboldt, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Covance Research, Madison, WI", 
                "last_name": "Debra Mandarino, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Covance Research - Daytona Beach, Fl", 
                "last_name": "H. Frank Farmer, PhD, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety assessments will be assessed by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical examinations, skin assessments, infusion site assessments, and AEs.", 
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "71 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929226"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "All PK parameters will be determined for a single intravenous administration of ETI-204.", 
                "measure": "Pharmacokinetics (PK) analysis", 
                "safety_issue": "No", 
                "time_frame": "71 Days"
            }, 
            {
                "description": "Immunogenicity measured by the percentage of subjects in each study arm with anti-ETI-204 antibody values greater than or equal to cutpoint at Day 1, 8, 43 and 71.", 
                "measure": "Anti-ETI-204 Antibody", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }
        ], 
        "source": "Elusys Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elusys Therapeutics", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}